Lentiviral vector containing ABCA4 gene ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
301	黄斑ジストロフィー	2

301. 黄斑ジストロフィー

---

臨床試験数 : 46 /  薬物数 : 42 - (DrugBank : 11) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 67

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-023111-34-NL (EUCTR)	24/02/2016	04/02/2016	A Phase I/IIa Study of SAR422459 in Patients With Stargardt Macular Degeneration	A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR422459, Administered to Patients with Stargardt's Macular Degeneration.	Stargardt Macular Dystrophy, also known as fundus flavimaculatus or Stargardt disease. MedDRA version: 18.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]	Product Name: SAR422459 Product Code: Lentiviral vector containing ABCA4 gene INN or Proposed INN: SAR422459	sanofi-aventis recherche et développement	NULL	Not Recruiting			Female: yes Male: yes	46	Phase 1/2	France;United States;Netherlands;Italy
2	EUCTR2010-023111-34-FR (EUCTR)	18/07/2011	08/03/2012	A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected StarGen, Administered to Patients with Stargardt's Macular Degeneration.	A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected StarGen, Administered to Patients with Stargardt's Macular Degeneration.	Stargardt Macular Dystrophy, also known as fundus flavimaculatus or Stargardt disease.	Product Name: StarGen Product Code: Lentiviral vector containing ABCA4 gene INN or Proposed INN: StarGen	Oxford BioMedica (UK) Ltd	NULL	Not Recruiting			Female: yes Male: yes	28	Phase 1;Phase 2	Netherlands;Italy;France